Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401670 | 1.00 | RAPGEF4 (0.56) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30977785 | 0.98 | RAPGEF4 (0.54) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1012671 | 0.98 | RAPGEF4 (0.54) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19837651 | 0.95 | RAPGEF4 (0.52) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL9850864 | 0.89 | MEN1 (0.56) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL12819946 | 0.81 | RAPGEF4 (0.52) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30951588 | 0.80 | RAPGEF4 (0.54) | RAPGEF4MEN1KMT2AALDH1A1HTT | |
| SCHEMBL838148 | 0.80 | RAPGEF4 (0.54) | RAPGEF4MEN1KMT2AALDH1A1HTT | |
| SCHEMBL30320262 | 0.79 | RAPGEF4 (0.74) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1334869 | 0.79 | RAPGEF4 (0.74) | RAPGEF4MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241824-B1 | TRIFLUOROACETHYDRAZIDE COMPOUND AS WELL AS PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN PREPARING A MEDICAMENT | GUANGZHOU MAGPIE PHARMACEUTICALS CO LTD (CN) | 2021-04-28 | — | — | EP | claimed |
| CN-105503939-B | O-methoxy phenylhydrazone double-core titanium complex and its preparation method and application | 山西大学 | 2017-12-05 | — | — | CN | claimed |
| EP-3241824-A1 | TRIFLUOROACETHYDRAZIDE COMPOUND AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PREPARING MEDICAMENT | Guangzhou Magpie Pharmaceuticals Co., Ltd. (CN) | 2017-11-08 | — | — | EP | claimed |
| CN-105503939-A | O-methoxy phenylhydrazone dicaryon metal complex and preparation method and application thereof | UNIV SHANXI | 2016-04-20 | — | — | CN | claimed |
| EP-0918052-B1 | Improved polymeric mdi color | BAYER AG (US) | 2003-05-28 | — | — | EP | claimed |
| US-4205155-A | Process for the production of poly(allyl halide amine silicate) reaction products | BLOUNT DAVID H | 1980-05-27 | — | — | US | claimed |
| US-4100112-A | Process for the production of amine silicate compounds and their resinous condensation products | BLOUNT DAVID H | 1978-07-11 | — | — | US | claimed |
| US-20260108481-A1 | COMPOUNDS FOR PREVENTION AND TREATMENT OF HEMORRHAGE AND VASCULATURE INSTABILITY | ABREXA PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260076926-A1 | COMPOUNDS FOR USE IN ORGAN PRESERVATION AND ORGAN TRANSPLANTATION | ABREXA PHARMACEUTICALS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12496281-B2 | Compounds for prevention and treatment of hemorrhage and vasculature instability | ABREXA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3931179-B1 | COMPOUNDS FOR PREVENTION AND TREATMENT OF OBESITY AND RELATED DISORDERS | ABREXA PHARMACEUTICALS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12357596-B2 | Compounds for prevention and treatment of obesity and related disorders | ABREXA PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3931178-B1 | COMPOUNDS FOR PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION | ABREXA PHARMACEUTICALS INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-4147713-A | Process for the production of halohydrin reaction products utilizing cyanide silicate compounds | BLOUNT DAVID H | 1979-04-03 | — | — | US | disclosed |
| US-4100112-A | Process for the production of amine silicate compounds and their resinous condensation products | BLOUNT DAVID H | 1978-07-11 | — | — | US | disclosed |
| US-4089840-A | Process for the production of epoxy silicate resinous products | BLOUNT DAVID H | 1978-05-16 | — | — | US | disclosed |
| US-4087407-A | Process for the production of epoxy silicate foam | BLOUNT DAVID H | 1978-05-02 | — | — | US | disclosed |
| US-4086190-A | Process for the production of silicic epoxy polymers | BLOUNT DAVID H | 1978-04-25 | — | — | US | disclosed |
| US-4012232-A | Stabilized photochromic materials | Chu, Nori Y. C. (US) | 1977-03-15 | — | — | US | disclosed |
| US-3966900-A | INSECTICIDES | AIRWICK INDUSTRIES, INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496281-B2 | Compounds for prevention and treatment of hemorrhage and vasculature instability | SERPINC1, PLAT, PLG | RAPGEF4 2382/4885MEN1 3327/4885KMT2A 4701/4885 |
| US-12357596-B2 | Compounds for prevention and treatment of obesity and related disorders | FABP4, GPR119, FABP6 | RAPGEF4 2434/4885MEN1 3155/4885KMT2A 2267/4885 |
| US-20260108481-A1 | COMPOUNDS FOR PREVENTION AND TREATMENT OF HEMORRHAGE AND VASCULATURE INSTABILITY | F11, F2, F3 | RAPGEF4 4686/4885MEN1 1307/4885KMT2A 3641/4885 |
| US-20260076926-A1 | COMPOUNDS FOR USE IN ORGAN PRESERVATION AND ORGAN TRANSPLANTATION | CASP9, CASP3, CASP10 | RAPGEF4 4761/4885MEN1 4523/4885KMT2A 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.